Search - tctmd.com

Displaying 141 - 160 of 256

Sort: Relevancy | Date

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Caitlin E. Cox

February 07, 2020

News Daily News

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Michael O'Riordan

February 05, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

Todd Neale

October 31, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Yael L. Maxwell

October 10, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Genes Bolster Case for Link Between Insomnia and CV Risk

Alison Palkhivala

August 19, 2019

News Conference News EAS 2019

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

Michael O'Riordan

May 30, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

Advertisement

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

TCTMD’s Top 10 Most Popular Stories for October 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Genes Bolster Case for Link Between Insomnia and CV Risk

Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content